Exagen (XGN) EBIAT (2018 - 2025)
Historic EBIAT for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to -$7.1 million.
- Exagen's EBIAT fell 4095.07% to -$7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.0 million, marking a year-over-year decrease of 1247.71%. This contributed to the annual value of -$15.1 million for FY2024, which is 3619.4% up from last year.
- Per Exagen's latest filing, its EBIAT stood at -$7.1 million for Q3 2025, which was down 4095.07% from -$4.4 million recorded in Q2 2025.
- Exagen's 5-year EBIAT high stood at -$3.0 million for Q2 2024, and its period low was -$14.7 million during Q2 2022.
- For the 5-year period, Exagen's EBIAT averaged around -$6.8 million, with its median value being -$6.2 million (2021).
- Per our database at Business Quant, Exagen's EBIAT crashed by 12878.32% in 2022 and then surged by 6581.66% in 2023.
- Quarter analysis of 5 years shows Exagen's EBIAT stood at -$7.1 million in 2021, then tumbled by 103.52% to -$14.4 million in 2022, then soared by 61.17% to -$5.6 million in 2023, then soared by 32.51% to -$3.8 million in 2024, then tumbled by 88.43% to -$7.1 million in 2025.
- Its EBIAT was -$7.1 million in Q3 2025, compared to -$4.4 million in Q2 2025 and -$3.8 million in Q1 2025.